Jazz Pharmaceuticals completed the acquisition of Chimerix for $935m.

Jazz Pharmaceuticals, a global biopharmaceutical company with a focus on oncology and neuroscience, completed the acquisition of Chimerix, a biopharmaceutical company, for $935m. "Bringing Chimerix into Jazz adds a novel medicine to our oncology portfolio and advances our efforts to address unmet patient needs. Dordaviprone has the potential to become the first and only FDA-approved therapy for patients with H3 K27M-mutant diffuse glioma and offers a promising near-term commercial opportunity, if approved. We are excited to welcome Chimerix's talented team as we collectively continue to advance dordaviprone, leveraging our development and commercial capabilities to deliver this therapy to patients as soon as the second half of this year," Bruce Cozadd, Jazz chairman and CEO.